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Abstract
Purpose To estimate the contribution of cryopreservation to the cumulative live birth rate (CLBR) after law modification in Italy
in the era of vitrification and freeze-all.
Methods The Italian National Registry performed a cycle-based data collection. Nine Italian IVF clinics were involved incor-
porating a total of 10,260 fresh cycles performed between January 2015 and April 2016 resulting in 9273 oocyte retrievals and
3266 subsequent warming cycles from the same oocyte retrievals performed up to December 2016. Mean female age was 37 ±
4.3 years. Primary outcome measure was CLBR per oocyte retrieval. Confounding factors were tested in multivariate regression
analysis, and the relative impact of cryopreservation to the CLBR in different patient categories was calculated.
Results CLBR per oocyte retrieval was 32.6%, 26.5%, 18.7%, 13.0%, and 5.5% for women younger than 36, aged 36–39, 40–
41, and older than 41 years, respectively. The total relative contribution of oocyte/embryo cryopreservation was 40.6% (95% CI
38.41–42.75). An association between maternal age, number of oocytes retrieved, fertilization rate, cryopreservation, and
cumulative live birth was shown. When adjusted for confounders, a 2.3-fold increase was observed in the chance of live birth
when cryopreservation was performed (OR 2.3; 95% CI 1.99–2.56). In high responder patients (> 15 oocytes retrieved) where
freeze-all was applied in 67.6% of cycles to avoid the risk of hyper stimulation syndrome, the relative contribution of vitrification
to the CLBR was 80.6%.
Conclusions Cryopreservation is essential in IVF and should always be available to patients to optimize success rates.
Multicentric, cycle-based data analyses are crucial to provide infertile couples, clinicians, and regulatory bodies with accurate
information on IVF effectiveness including fresh and cryopreserved cycles.
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Introduction
The Italian Registry of ART is responsible by law to retro-
spectively collect baseline information and IVF outcomes of
all treatment cycles performed in Italy since 2004 (Repubblica
Italiana, Law 40/2004). Only summary data were collected up
until now, with clear limitations in data analysis. The cumula-
tive chance of success, including fresh and cryopreserved cy-
cles, cannot for instance be calculated if cycle-based data are
not available. In turn, infertile couples, clinicians, and regula-
tory bodies cannot have a real picture of the effectiveness of
IVF treatments across the country. These aspects are particu-
larly important in those countries where law limitations are in
force. For instance, in Italy, embryo cryopreservation was
strictly forbidden from 2004 and 2009, when only oocyte
cryopreservation could be applied.1–4 Since 2009, embryo
cryopreservation can be performed with the aim to protect
women’s health (Corte Costituzionale 2009)5, 6 (i.e., to min-
imize the risks of ovarian hyperstimulation syndrome and/or
multiple pregnancy and to optimize the chance of success
according to medical indication). To be able to calculate the
impact of this change in regulations on a patient’s chance of
success, CLBR including fresh and cryopreserved cycles need
to be carefully estimated.
The aim of this study is to calculate the contribution of
cryopreservation to the CLBR in different patient populations
by analysis of cycle-based data collected from 9 representative
Italian IVF clinics.
Materials and methods
Source of data In January 2016, new software was developed
by the Italian National Registry allowing individual data col-
lection from single IVF treatments based on the same items
that were previously collected in a cumulative form. The soft-
ware was then implemented in December 2016 in 9 voluntary
representative Italian IVF clinics for the number of cycles
performed annually and type of service (public and private)
(Table 1). Variables were validated based on the experience of
a Lombardy county pilot data collection program of single
IVF treatments (Assisted Reproductive Technology
Lombardia Network).
Data were collected retrospectively for all consecutive au-
tologous IVF cycles undertaken between January 2015 and
December 2016. For the purpose of the analysis, 10,260 fresh
cycles performed between 1 January 2015 and 30 April 2016
resulting in 9273 oocyte retrievals and 3266 subsequent
warming cycles from the same oocyte retrievals performed
up to December 2016 were included (Fig.1 study design).
Only one fresh IVF cycle per patient was included. Oocyte
retrieval cycles that were performed for fertility preservation
purposes and donor cycles were excluded.
Variables N = 102 variables for each cycle were collected, in-
cluding patient and cycle characteristics. In particular, mater-
nal age, paternal age, cause of infertility, ovarian stimulation
protocol, source of gametes, sperm quality, number of collect-
ed, mature and inseminated oocytes, fertilized oocytes, em-
bryos and blastocysts obtained, transferred and cryopreserved,
pregnancy, miscarriage, delivery, and neonatal outcomes
(birth weight and weeks of gestation) were collected. The
primary outcome measure was cumulative live birth rate
(CLBR) defined as the number of deliveries with at least one
live birth resulting from one oocyte retrieval cycle, including
all cycles in which fresh and/or frozen embryos were trans-
ferred, until one delivery with a live birth occurred or until all
embryos were used, whichever occurred first. The delivery of
a singleton, twin, or other multiples was registered as one
delivery.7, 8
RegulationBriefly, in Italy, no restriction exists with respect to
the ovarian stimulation protocol to adopt and/or to the number
of embryos to be transferred simultaneously. The number of
oocytes to be inseminated is not anymore defined by law but
has to be decided and certified by the clinician according to
the best clinical practice and the estimated chance of pregnan-
cy for each patient. Of note, all the viable embryos produced
must be either transferred or cryopreserved, regardless of their
morphological/genetic quality, and they cannot be discarded
or donated for research purposes. Preimplantation genetic test-
ing is possible also for fertile couples. Surrogacy is not
allowed.
Statistical analysis Univariate and multivariate logistic regres-
sions were performed to evaluate associations with CLBR. The
model included the following patient and cycle characteristics:
maternal age, paternal age, cause of infertility, ovarian stimula-
tion protocol, source of spermatozoa, sperm quality, number of
collected, mature and inseminated oocytes, type of insemination
procedure (IVF vs ICSI), fertilized oocytes, cryopreservation,
and IVF center. We tested all two-way interactions between
pairs of predictors included in our multivariate analyses and
used a Bonferroni correction (for multiple testing) p value
threshold of 0.05 to define statistical evidence of an interaction.
The predictive value of the resulting model was assessed by
calculating the area under the curve of receiver operator charac-
teristics (AUROC). To evaluate the level of agreement between
the estimated and the observed probabilities (calibration), the
Hosmer-Lemeshow test was used. All statistical analyses were
performed using IBM SPSS Statistics 23.
Results
The overall CLBR was 21.7% per oocyte retrieval (95% CI
20.88–22.57). Mean female age was 37 ± 4.3 years. The
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patient population was distributed as follow: 34.6% younger
than 36, 32.9% aged 36–39, 17.3% 40–41, and 15.2% older
than 41 years. Causes of infertility were tubal (11.3%), anovu-
latory (2.9%), endometriosis (3.9%), male (26.1%), combina-
tion of known causes (23.3%), and unknown cause (32.6%).
The intervention period in this study was 24 months,
16 months for oocyte retrievals and a minimum of 8 months
for subsequent cryo-cycles (completion period). To under-
stand the time needed to complete an IVF cycle, three different
periods were analyzed: period 1 = patients that performed in-
tervention in the first 8 months, followed up by a completion
period of 16 months; period 2 = patients that performed
intervention between 8 and 12 months from the beginning of
the study period, followed up by a completion period of
12 months; period 3 = patients that performed intervention
between 12 and 16 months from the beginning of the obser-
vation period, followed up by a completion period of 8months
(Fig. 1).
A total of 8240 cycles (89.9%CI 89.3–90.5) were conclud-
ed at the time of the analysis, with either a delivery or no
supernumerary available oocytes or embryos still cryopre-
served. When analyzing treatment discontinuation (no preg-
nancy obtained but cryopreserved embryos or oocytes still
available), according to the completion period, we observed
Table 1 ART centers involved in the study
ART centers Type of service City/region All fresh IVF cycles
2015–2016
Fresh IVF retrievals
included in the study
N % of the total
number of cycles
N % of the total
number of retrievals
included
Centro Medicina della Riproduzione - AOU
città della Salute e della Scienza di Torino
- Ospedale Sant’Anna
Public Torino/Piemonte 901 4.8 528 5.7
IRCCS Istituto Clinico Humanitas -
Dipartimento di Ginecologia e Medicina
della Riproduzione
Private covered
by NHS
Milano/Lombardia 4.875 26.0 2.586 27.9
SSD Procreazione Medicalmente Assistita -
IRCCS Burlo Garofalo
Public Trieste/Friuli Venezia
Giulia
694 3.7 385 4.2
Centro per la Diagnosi e la Terapia della
Sterilità Involontaria di Coppia
“P-Bertocchi”- A.O. Arcispedale
S. Maria Nuova
Public Reggio Emilia/Emilia
Romagna
2.425 12.9 1.223 13.2
9.baby - Family and Fertility Center,
Tecnobios Procreazione, Bologna
Private Bologna/Emilia Romagna 1.245 6.6 595 6.4
SOD di Procreazione Medicalmente
Assistita - Università degli Studi di
Firenze - A.O. Careggi
Public Firenze/Toscana 1.321 7.0 577 6.2
Centro di Procreazione Assistita “Demetra” Private covered
by NHS
Firenze/Toscana 3.226 17.2 1.628 17.6
Medicina e Biologia della Riproduzione -
European Hospital
Private Roma/Lazio 1.546 8.2 754 8.1
GENERA - Clinica Valle Giulia - Casa di
cura - SPA
Private Roma/Lazio 2.540 13.5 997 10.8
Fig. 1 Study design. Intervention period = period during which oocyte
retrievals have been performed. Completion period = period following
oocyte retrievals where warming cycles are performed. Period 1 =
patients that performed intervention in the first 8 months, followed up
by a completion period of 16 months; period 2 = patients that performed
intervention between 8 and 12 months from the beginning of the study
period, followed up by a completion period of 12 months; period 3 =
patients that performed intervention between 12 and 16 months from the
beginning of the observation period, followed up by a completion period
of 8 months
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that 13.9%, 11.9%, and 9.9% of cycles were not concluded
during the periods of 8 months, 12 months, and 16 months
following oocyte retrievals, respectively (Table 2).
A total of 1197 LB were obtained after fresh embryo trans-
fers (12.9% per oocyte retrieval and 20.3% per transfer). A
total of 483 oocytes, 817 embryos, and 1563 blastocysts ob-
tained from the same oocyte retrieval cycles were warmed.
Survival rates were 77.3%, 85.7%, and 96.4%; respectively.
An additional 817 deliveries were obtained after warming
embryo transfers (25.0% per cycle and 25.9% per transfer)
(Fig.2). A total of 40.6% of all live births included in the
CLBR were a result of cryopreservation. In particular, oocyte
cryopreservation contributed only 0.3% (6) instead of transfer
of thawed embryos that contributed 40.3% (811). The multi-
variate analysis showed an association between patient (ma-
ternal age), cycle (number of oocytes retrieved, fertilization
rate, and cryopreservation) characteristics, and CLBR per oo-
cyte retrieval (Table 3). The predictive value of the model was
moderate with AUCROC = 0.75 (p < 0.001).
As expected, the probability of live birth significantly de-
creased with increasing maternal age. However, cryopreserva-
tion significantly contributed to the success rate in all patient
populations (the relative increase in LBRwas 41.4% for wom-
en younger than 36, 43.8% aged 36–39, 36.7% 40–41, and
39.0% for those older than 41 years) (Fig. 3).
Increasing the number of oocytes retrieved resulted in higher
chance of success. Poor responders (< 3 oocytes) demonstrated
a significantly lower CLBR vs suboptimal responders (4–6
oocytes) (OR 1.7; 95% CI 1.41–2.17), normal responders (7–
10 oocytes) (OR 2.1; 95%CI 1.71–2.63), good responders (11–
15 oocytes) (OR 2.6; 95% CI 2.09–3.29), and high responders
(> 15 oocytes) (OR 2.7; 95%CI 2.10–3.41). It emerged that the
more oocytes were available, the greater the chance to obtain a
live birth when fresh and cryo-cycles were included. In partic-
ular, the relative contribution of cryopreservation to the CLBR
increased in relation to the ovarian response (9.6%, 16.5%,
31.0%, 45.3%, and 80.6% for poor, suboptimal, normal, good,
and high responders, respectively) (Fig. 4).
The use of ICSI was not significantly associated with the
CLBR (univariate OR = 1.1 and 95% CI 0.92–1.22). However,
a high fertilization rate (FR) increased the chance of success
independently from the insemination technique used and the
number of oocytes retrieved (when FR > 70%, OR = 2.4, and
95% CI 1.97–2.86). This could be attributed to the higher num-
ber of embryos available for transfer and cryopreservation and
thus to the higher relative contribution of cryopreservation to
the CLBR (25% vs 43%, for bad and good FR, respectively).
We observed the freeze-all approach to be efficient and safe
with no impact on the CLBR (univariate OR = 1.7 and 95%CI
1.53–1.93 while multivariate OR =NS). Ovarian hyperstimu-
lation syndrome (OHSS) was not reported when freeze-all
was adopted to avoid this complication (N = 924; 9.0% of
cycles), while 12 cases (0.13%) of severe OHSS were identi-
fied after fresh embryo transfers. Thromboembolic events
were not reported. It is important to note that in the high
responder population (> 15 oocytes retrieved), the relative im-
pact of cryopreservation was as high as 80.6% due to greater
application of the freeze-all strategy aimed at increasing cycle
safety (67.6% of oocyte retrievals).
Discussion
National Registries have the responsibility to provide reliable
reporting of IVF outcomes. The primary concern in the esti-
mation of IVF success rate is the overall chance of at least one
delivery including both fresh and cryopreserved oocyte/
embryo transfers from the same oocyte retrieval. A second
important challenge is to inform patients, clinicians, and reg-
ulatory bodies about safety issues by clearly reporting the risks
associated with the technology and clinical management.
The Italian National Registry publishes age-stratified out-
come rates annually. Summary data collection, however, can
only separately calculate fresh and cryopreserved cycle out-
comes while cumulative success rates can only be estimated.
Due to new advances in cryopreservation since the introduc-
tion of vitrification into IVF laboratories (reviewed by9), fresh
cycles alone are poorly representative of the overall success
rate.10 The present study, performed on cycle-based data col-
lection, shows for the first time in Italy the real contribution of
Table 2 Discontinuation according to the completion period starting
from oocyte retrieval date (see Fig. 1). Discontinuation of the treatment =
cycle not concluded (no pregnancy obtained but cryopreserved embryos/
oocytes still available). Completion period = period following oocyte
retrieval date where warming cycles are performed
Completion period
Intervention period 1 considering 16 months for
completion
Intervention period 1 + 2 considering 12 months
for completion
Intervention period 1 + 2 + 3 considering
8 months for completion
N cycles Discontinuation of
the treatment
% discontinuation
of the treatment
N
cycles
Discontinuation of
the treatment
% discontinuation
of the treatment
N
cycles
Discontinuation of
the treatment
% discontinuation
of the treatment
4.936 487 9.9 7.028 836 11.9 9.273 1.286 13.9
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Table 3 Logistic regression
analysis adjusted for significant
patients and cycle confounders
Characteristic Categories Univariable odds ratio
of live birth (95% CI)
Multivariablea odds ratio
of live birth (95% CI)
p valueb
Maternal age (years) ≤ 35 1 1 < 0.001
36–37 0.743 (0.647–0.853) 0.793 (0.685–0.918)
38–39 0.478 (0.413–0.553) 0.59 (0.506–0.688)
40–41 0.31 (0.263–0.365) 0.433 (0.365–0.515)
≥ 42 0.119 (0.094–0.152) 0.189 (0.148–0.243)
Retrieved oocytes ≤ 3 1 1 < 0.001
4–6 2.923 (2.38–3.59) 1.751 (1.413–2.171)
7–10 4.589 (3.762–5.598) 2.12 (1.712–2.626)
11–15 6.919 (5.64–8.489) 2.627 (2.095–3.295)
> 15 8.878 (7.175–10.985) 2.679 (2.105–3.41)
Fertilization rate < 50% 1 1 < 0.001
50–70% 2.263 (1.876–2.731) 1.8 (1.477–2.193)
> 70% 3.286 (2.762–3.91) 2.378 (1.974–2.865)
Cryopreservation No 1 1 < 0.001
Yes 4.466 (4.019–4.963) 2.256 (1.986–2.563)
aMultivariable adjusted =mutual adjustment for uncorrelated significant variables listed in column 1
b p value for multivariable association
Fig. 2 Flow-chart of the study.
Discontinuation represents the
number of patients that had not
completed their treatment with
oocytes and/or embryos still
cryopreserved and no live birth
obtained
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cryopreservation to the CLBR in the new era of vitrification
and freeze-all. Our results confirm that the success rate is
clearly underestimated when only fresh transfers are
considered, i.e., in the young patient population, the live birth
rate per oocyte retrieval was 19.1% with fresh ET which in-
creased up to 32.6% when cryopreserved cycles were
Fig. 4 Live birth rate (LBR) per fresh cycle and cumulative LBR (CLBR) including fresh and warming cycles according to the number of oocytes
retrieved
Fig. 3 Live birth rate (LBR) per fresh cycle and cumulative LBR (CLBR) including fresh and warming cycles according to female age
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included; while in high responder patients, the live birth rate
increased from 7.4 to 38.3% when cryo-cycles were included
(relative increase of 80.6%). This latter figure is also due to the
large application of freeze-all aimed at reducing the risk of
hyperstimulation. Overall, it must be emphasized that embryo
cryopreservation was the main contributor to increased CLBR
compared with oocyte cryopreservation. In our study, more
than 1 pregnancy out of 3 was in fact obtained using cryopre-
served embryos. This finding underlines the importance of
this technology in IVF that should be available to all patients
to maximize their chance of success.
When embryo cryopreservation was allowed in Italy, it
resulted in a sudden application of this technology in spite of
the well-consolidated practice of cryopreserving oocytes.
There is a plethora of reasons that boosted such a change in
the clinical strategy. First of all was cost-benefit. Specifically,
whenever the reason for cryopreservation was not fertility
preservation for medical or non-medical reasons,11 but when
it was performed as part of a conventional IVF cycle, cryopre-
serving embryos as opposed to oocytes ensured a lower work-
load for the laboratories (single insemination procedure, less
embryos as compared with oocytes to be cryopreserved, and
higher cryo-survival rates, especially when dealing with blas-
tocysts). Moreover, observation of fertilization and early pre-
implantation development allows assessment of embryo de-
velopmental competence before short- or even long-term stor-
age is performed. Beyond strategic and logistical concerns,
technical reasons also supported the switch from oocyte to
embryo cryopreservation. Specifically, the oocyte is the larg-
est cell in humans, and its shape, the amount of water it con-
tains, and the permeability of its membrane make it more
fragile to all the cryopreservation-induced stresses, thereby
limiting the efficacy of such clinical practice. Indeed, higher
survival rates after cryopreservation have been consistently
reported for embryos compared with oocytes, especially when
vitrification protocols are adopted.9
To perform an analysis of CLBR that includes collectively
fresh and thawed cycles resulting from each oocyte collection,
a completion period following oocyte retrievals is necessary.
Our data show that 16 months of interventions (oocyte re-
trievals) followed by a minimum of 8 months of follow-up
(thawing cycles) are needed to obtain full information on
88.9% of oocyte retrievals (treatment discontinuation =
11.1%). Even when a 16-month period follow-up was possi-
ble for warming cycles (oocyte retrievals performed in the first
8-month period of the study), 9.9% of cycles were still not
concluded. Considering the whole study period, 1 patient out
of 3 among those not pregnant after the fresh embryo transfer
that had supernumerary cryopreserved oocytes/embryos did
not come back for their first warming cycle. The reasons that
induce patients to postpone or not perform their cryo-cycles
need further investigation. This could be partly due to a lack of
information about the real potential of cryopreserved embryos
to contribute to the success rate. Another possibility is that
couples move from one center to another before completing
their cycle. A better follow-up will be possible only when
cycle-based data analysis is implemented in all IVF centers
and a unique identification number is assigned to each indi-
vidual couple.
Our study reinforces previous findings related to the iden-
tification of variables affecting IVF success rates.12–18
Besides the obvious negative influence of maternal age, other
factors were also independently predictive of CLBR in our
cycle-based database. Here we assessed the contribution of
cryopreservation in association with specific patient and cycle
characteristics.
Our data confirm the clear positive relationship between
the numbers of oocytes available for insemination and
CLBR. Patients should thus be informed that the higher the
oocyte yield, the higher the probability of achieving a deliv-
ery, when both fresh and cryo-cycles are considered.
Moreover, our data also endorse the evidence that a high re-
sponse to ovarian stimulation, resulting in more than 15 oo-
cytes retrieved, does not impair the CLBR but, on the contrary,
increases the chance of success when subsequent warming
cycles are included. This finding is consistent with previous
recent reports based on CLBR.19, 20
The use of ICSI was previously shown to be an effective
treatment for male factor infertility.14, 16, 18 Our data con-
firm that when ICSI is consistently used (84.7% of cycles in
this study), male factor infertility is not a negative predictor of
CLBR. However, we found that a low fertilization rate (inde-
pendent of the insemination method) was associated with a
decreased chance to obtain a live birth because the contribu-
tion of cryopreservation was smaller in these cases. We sug-
gest that this parameter should be included as a confounder of
IVF success for future analysis.
In our analysis, freeze-all had no negative impact on the
CLBR. The new advances in cryobiology, with the introduc-
tion of vitrification for both oocyte and embryo cryopreserva-
tion, have now made this strategy routinely available to
clinics. The aims are to reduce the risks related to ART tech-
nology (namely OHSS) and/or to extend the time for embryo
evaluation. New prospects for increasing the safety and effi-
ciency of ART technology are thus expected in the near future
with the systematic use of cryopreservation.9, 21, 22
We believe that the outcomes of this study can considerably
help IVF centers to improve their results by adopting the best
strategies for clinical/embryological management. Principally,
ovarian stimulation strategies should be aimed at obtaining the
maximum number of oocytes, freeze-all approach should be
adopted to minimize the occurrence of OHSS without
impacting the overall results, and finally clinical management
should focus on encouraging oocyte/embryo-warming cycles
to improve CLBR. The access to and optimization of cryo-
preservation programs are in fact essential factors to ensure
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quality and safety of treatments. It is important to note that the
mean female age in our patient population was 37 ± 4.3 years
(with 65.4% of women over 35 years old). This is in line with
previous reports that have shown that the Italian population
undergoing IVF is particularly old compared with the rest of
Europe (De Geyter et al. 2018)23. However, the relative con-
tribution of cryopreservation was significant in all age groups
(> 35%) further underlining the importance of this technology
also for poor prognosis patients.
This study also shows that the potential of cycle-based data
analysis to assess CLBR and IVF Registers and Centers
should be encouraged to proceed with this approach.
Conclusions
Cycle-based data collection allows accurate analysis of cumu-
lative IVF outcomes to be performed, by identifying factors
that can affect the success of this procedure and those that may
induce adverse outcomes. Cryopreservation has become a key
factor allowing live birth rates in different patient populations
to be substantially improved. These analyses aim to facilitate
patient counseling, clinical decision-making, and informing
regulatory bodies about advancement of the technology.
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